EP3796915A4 - Orale formulierungen enthaltend rivaroxaban - Google Patents

Orale formulierungen enthaltend rivaroxaban Download PDF

Info

Publication number: EP3796915A4
Authority: EP; European Patent Office
Prior art keywords: rivaroxaban; oral formulations; formulations; oral
Prior art date: 2018-11-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP18940435.3A

Other languages

English (en)

French (fr)

Other versions

EP3796915A1 (de

Inventor

Ersin Yildirim

Bayram Kanik

Tansel AKTAS

Fatma ÖZTÜRK

Tuncay Gül

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Santa Farma Ilac Sanayi A S

Santa Farma Ilac Sanayi AS

Original Assignee

Santa Farma Ilac Sanayi A S

Santa Farma Ilac Sanayi AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-11-16

Filing date

2018-11-16

Publication date

2022-01-26

2018-11-16 Application filed by Santa Farma Ilac Sanayi A S, Santa Farma Ilac Sanayi AS filed Critical Santa Farma Ilac Sanayi A S

2021-03-31 Publication of EP3796915A1 publication Critical patent/EP3796915A1/de

2022-01-26 Publication of EP3796915A4 publication Critical patent/EP3796915A4/de

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP18940435.3A 2018-11-16 2018-11-16 Orale formulierungen enthaltend rivaroxaban Pending EP3796915A4 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/TR2018/050699 WO2020101587A1 (en)	2018-11-16	2018-11-16	Oral formulations comprising rivaroxaban

Publications (2)

Publication Number	Publication Date
EP3796915A1 EP3796915A1 (de)	2021-03-31
EP3796915A4 true EP3796915A4 (de)	2022-01-26

Family

ID=70732156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18940435.3A Pending EP3796915A4 (de)	2018-11-16	2018-11-16	Orale formulierungen enthaltend rivaroxaban

Country Status (2)

Country	Link
EP (1)	EP3796915A4 (de)
WO (1)	WO2020101587A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11654036B2 (en) *	2020-05-26	2023-05-23	Elixir Medical Corporation	Anticoagulant compounds and methods and devices for their use
WO2023067620A1 (en) *	2021-10-18	2023-04-27	Unison Pharmaceuticals Pvt. Ltd.	Orally disintegrating pharmaceutical compositions of rivaroxaban
CN114886867A (zh) *	2022-06-16	2022-08-12	北京四环制药有限公司	一种高稳定性的利伐沙班药物组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103550165A (zh) *	2013-10-19	2014-02-05	浙江华海药业股份有限公司	一种含有利伐沙班的药物组合物及其制备方法
CN105267169A (zh) *	2015-12-07	2016-01-27	石家庄康贺威药业有限公司	一种利伐沙班片剂及其制备方法
WO2016166733A1 (en) *	2015-04-17	2016-10-20	Micro Labs Limited	A process for preparing a pharmaceutical composition comprising rivaroxaban
US20170065526A1 (en) *	2015-09-08	2017-03-09	Shaoping Wang	Solid dosage form of rivaroxaban and methods for making the same
WO2017146709A1 (en) *	2016-02-25	2017-08-31	Mylan Inc.	A unique high-shear granulation process for improved bioavailability of rivaroxaban

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10300111A1 (de)	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PT1934208E (pt)	2005-10-04	2011-06-01	Bayer Schering Pharma Ag	Nova forma polimorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3- oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2- tiofenocarboxamida
US7985750B2 (en)	2007-08-14	2011-07-26	Concert Pharmaceuticals, Inc.	Substituted oxazolidinone derivatives
DE102007048705A1 (de)	2007-10-11	2009-04-16	Bayer Healthcare Ag	Amorphe Formulierung
ES2606127T5 (es)	2009-06-18	2020-02-17	Krka Tovarna Zdravil D D Novo Mesto	Composición farmacéutica sólida que comprende rivaroxabán
US20120231076A1 (en)	2009-10-06	2012-09-13	Ratiopharm Gmbh	Pharmaceutical compositions comprising rivaroxaban
IN2014MU00781A (de) *	2014-03-07	2015-09-25	Torrent Pharmaceuticals Ltd
EP2929885A1 (de)	2014-04-11	2015-10-14	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmazeutische kombinationen von rivaroxaban und protonenpumpenhemmern
EP2942058A1 (de)	2014-05-09	2015-11-11	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmazeutische Kombinationen aus Rivaroxaban und Histamin-H2-Rezeptorantagonisten
TR201501970A2 (en)	2015-02-19	2016-09-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical combinations of dronedarone.
US20180214453A1 (en)	2015-08-05	2018-08-02	Interquim, S.A.	Rivaroxaban pharmaceutical compositions

2018
- 2018-11-16 EP EP18940435.3A patent/EP3796915A4/de active Pending
- 2018-11-16 WO PCT/TR2018/050699 patent/WO2020101587A1/en not_active Ceased

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103550165A (zh) *	2013-10-19	2014-02-05	浙江华海药业股份有限公司	一种含有利伐沙班的药物组合物及其制备方法
WO2016166733A1 (en) *	2015-04-17	2016-10-20	Micro Labs Limited	A process for preparing a pharmaceutical composition comprising rivaroxaban
US20170065526A1 (en) *	2015-09-08	2017-03-09	Shaoping Wang	Solid dosage form of rivaroxaban and methods for making the same
CN105267169A (zh) *	2015-12-07	2016-01-27	石家庄康贺威药业有限公司	一种利伐沙班片剂及其制备方法
WO2017146709A1 (en) *	2016-02-25	2017-08-31	Mylan Inc.	A unique high-shear granulation process for improved bioavailability of rivaroxaban

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020101587A1 *

Also Published As

Publication number	Publication date
EP3796915A1 (de)	2021-03-31
WO2020101587A1 (en)	2020-05-22

Publication	Publication Date	Title
EP3886820B8 (de)	2023-05-17	Kapselformulierungen
EP3895682A4 (de)	2022-08-17	Dentale zusammensetzung
EP3781135A4 (de)	2021-12-29	Feste orale pharmazeutische zusammensetzungen mit sitagliptin
EP3701930A4 (de)	2021-07-21	Dentale zusammensetzung
EP4015001A4 (de)	2023-06-14	Orale pharmazeutische zusammensetzung
IL290356A (en)	2022-04-01	Formulations for Resotide
EP3746078A4 (de)	2021-11-17	Orale formulierungen und verwendungen davon
GB201904338D0 (en)	2019-05-15	Fluorouracil-containing formulations
IL284691A (en)	2021-08-31	formulations
EP3796915A4 (de)	2022-01-26	Orale formulierungen enthaltend rivaroxaban
EP3858322A4 (de)	2022-06-22	Dentale zusammensetzung
EP3510990A4 (de)	2020-03-25	Orale zusammensetzung
EP3962605A4 (de)	2023-05-10	Mundpflegezusammensetzung
EP3904282A4 (de)	2022-10-26	Zusammensetzung für die mundhöhle
SG11202010097WA (en)	2020-11-27	Apixaban formulations
EP3764991A4 (de)	2022-12-07	Impfstoffzusammensetzung
AU2016432930B2 (en)	2020-01-30	Oral care compositions including charcoal
EP3811787A4 (de)	2022-04-06	Orale zusammensetzung
EP3512507A4 (de)	2019-11-13	Orale arzneimittelformulierungen
HK40115589A (zh)	2025-04-03	包含依鲁替尼的配制品/组合物
HK40052508A (en)	2022-01-21	Oral formulations of branaplam
AU2020333555A1 (en)	2022-03-10	Larazotide formulations
HK40076338A (en)	2023-02-10	Larazotide formulations
HK40063859A (en)	2022-06-24	Improved vaccine formulations
EP4034072A4 (de)	2023-11-08	Mundpflegezusammensetzung

Legal Events

Date	Code	Title	Description
2020-05-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-02-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-02-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-03-31	17P	Request for examination filed	Effective date: 20201221
2021-03-31	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-03-31	AX	Request for extension of the european patent	Extension state: BA ME
2022-01-26	A4	Supplementary search report drawn up and despatched	Effective date: 20220104
2022-01-26	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/16 20060101ALI20211221BHEP Ipc: A61K 9/20 20060101ALI20211221BHEP Ipc: A61P 7/02 20060101ALI20211221BHEP Ipc: A61K 31/5377 20060101AFI20211221BHEP
2022-02-23	DAV	Request for validation of the european patent (deleted)
2022-02-23	DAX	Request for extension of the european patent (deleted)
2024-05-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-06-26	17Q	First examination report despatched	Effective date: 20240528